Cytosorbents financials
$4.00−0.50%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.6M | $8.9M | $9.2M | $9.5M | $9.6M | $8.7M | $9.2M | $8.6M | $8.8M | $9.0M | $3.4M | $8.8M |
| Gross profit | $7.0M | $6.1M | $6.8M | $6.7M | $6.8M | $6.2M | $6.3M | $5.3M | $6.5M | $6.9M | $4.9M | $5.6M |
| Gross margin | 73.2% | 69.2% | 73.7% | 70.3% | 70.9% | 71.1% | 68.4% | 61.0% | 73.5% | 76.5% | 143.1% | 63.6% |
| Operating income | -$2.6M | -$3.0M | -$4.4M | -$2.9M | -$3.6M | -$3.9M | -$3.4M | -$4.8M | -$3.6M | -$4.7M | -$10.1M | -$7.4M |
| Net income | -$4.4M | -$5.1M | -$5.5M | -$3.2M | $1.9M | -$1.5M | -$7.6M | -$2.8M | -$4.3M | -$6.1M | -$6.6M | -$9.2M |
| Net margin | −45.9% | −57.9% | −59.5% | −33.4% | 20.2% | −16.9% | −82.7% | −32.1% | −48.6% | −67.7% | −193.1% | −104.3% |
| Diluted EPS | $-1.40 | $-1.60 | $-1.89 | $-1.00 | $0.60 | $-0.40 | $-3.01 | $-1.00 | $-1.60 | $-2.20 | $-2.82 | $-4.20 |
| EBITDA | -$2.0M | -$2.7M | -$3.5M | -$2.5M | -$3.2M | -$3.5M | -$3.0M | -$4.4M | -$3.2M | -$4.3M | -$9.7M | -$6.9M |
| Operating cash flow | -$583.0K | -$1.2M | -$4.8M | -$2.6M | -$1.5M | -$3.5M | -$2.3M | -$2.5M | -$4.8M | -$4.8M | -$6.4M | -$5.2M |
| Free cash flow | -$597.0K | -$1.2M | -$4.9M | -$2.6M | -$1.5M | -$3.5M | -$2.4M | -$2.6M | -$4.8M | -$4.9M | -$6.5M | -$5.3M |
| Diluted shares | 3.1M | 3.1M | 2.9M | 3.1M | 3.4M | 3.0M | 2.5M | 2.7M | 2.7M | 2.9M | 2.3M | 2.2M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $4.4M | $4.8M | $6.2M | $7.5M | $10.2M | $11.6M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $17.2M | $17.0M | $16.7M | $14.6M | $14.4M | $14.2M |
| Total assets | $38.0M | $40.6M | $44.2M | $45.8M | $48.0M | $50.8M |
| Total liabilities | $38.7M | $38.4M | $38.3M | $36.7M | $36.4M | $36.2M |
| Shareholders' equity | -$751.0K | $2.2M | $5.9M | $9.0M | $11.6M | $14.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology